Loading…
Twice Weekly Fluconazole Prophylaxis for Prevention of Invasive Candida Infection in High-risk Infants of <1000 Grams Birth Weight
We tested the hypothesis that twice weekly prophylactic dosing of fluconazole prevents invasive candidiasis without promoting resistant Candida species in high-risk, preterm infants. We compared our previous dosing schedule (Group A) to a less frequent dosing schedule of twice a week (Group B) of fl...
Saved in:
| Published in: | The Journal of pediatrics 2005-08, Vol.147 (2), p.172-179 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c387t-fe0508c877e74ad647157bfdd724879b7e3e65a9d01f869d9c51410e0f793663 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c387t-fe0508c877e74ad647157bfdd724879b7e3e65a9d01f869d9c51410e0f793663 |
| container_end_page | 179 |
| container_issue | 2 |
| container_start_page | 172 |
| container_title | The Journal of pediatrics |
| container_volume | 147 |
| creator | Kaufman, David Boyle, Robert Hazen, Kevin C. Patrie, James T. Robinson, Melinda Grossman, Leigh B. |
| description | We tested the hypothesis that twice weekly prophylactic dosing of fluconazole prevents invasive candidiasis without promoting resistant
Candida species in high-risk, preterm infants.
We compared our previous dosing schedule (Group A) to a less frequent dosing schedule of twice a week (Group B) of fluconazole prophylaxis for up to 6 weeks in a prospective, randomized, double-blind clinical trial in preterm infants weighing |
| doi_str_mv | 10.1016/j.jpeds.2005.03.036 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68528756</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022347605002507</els_id><sourcerecordid>68528756</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-fe0508c877e74ad647157bfdd724879b7e3e65a9d01f869d9c51410e0f793663</originalsourceid><addsrcrecordid>eNp9kM-LEzEUx4Mobl39CwTJRW9TXyYzyQzoQYv7Axb0UPAY0uTFpjtNajKt1qN_uZltYW_Cg5CXz_fl8SHkNYM5Aybeb-abHdo8rwHaOfBS4gmZMehlJTrOn5IZQF1XvJHigrzIeQMAfQPwnFwwwWoBTTsjf5e_vEH6HfF-ONKrYW9i0H_igPRbirv1cdC_faYupnLHA4bRx0Cjo7fhoLM_IF3oYL3VpeHQPLz6QG_8j3WVfL6f2jqMeYp8YGUBep30NtPPPo3r8mvhxpfkmdNDxlfn85Isr74sFzfV3dfr28Wnu8rwTo6VQ2ihM52UKBttRSNZK1fOWlk3nexXEjmKVvcWmOtEb3vTsoYBgpM9F4JfknensbsUf-4xj2rrs8Fh0AHjPivRtXUn2wnkJ9CkmHNCp3bJb3U6KgZqMq826sG8mswr4KWm1Jvz-P1qi_Yxc1ZdgLdnQGejB5d0MD4_cpJxKWoo3McTh8XFwWNS2XgMBq1PxbCy0f93kX_1paJd</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68528756</pqid></control><display><type>article</type><title>Twice Weekly Fluconazole Prophylaxis for Prevention of Invasive Candida Infection in High-risk Infants of <1000 Grams Birth Weight</title><source>ScienceDirect Journals</source><creator>Kaufman, David ; Boyle, Robert ; Hazen, Kevin C. ; Patrie, James T. ; Robinson, Melinda ; Grossman, Leigh B.</creator><creatorcontrib>Kaufman, David ; Boyle, Robert ; Hazen, Kevin C. ; Patrie, James T. ; Robinson, Melinda ; Grossman, Leigh B.</creatorcontrib><description>We tested the hypothesis that twice weekly prophylactic dosing of fluconazole prevents invasive candidiasis without promoting resistant
Candida species in high-risk, preterm infants.
We compared our previous dosing schedule (Group A) to a less frequent dosing schedule of twice a week (Group B) of fluconazole prophylaxis for up to 6 weeks in a prospective, randomized, double-blind clinical trial in preterm infants weighing <1000 grams at birth and with an endotracheal tube and/or central vascular catheter over a 24-month period. Weekly surveillance cultures were obtained on study patients.
Candida colonization was documented in 5 (12%) of 41 Group A and in 4 (10%) of 40 Group B infants.
Candida sepsis developed in two (5%) of Group A and one (3%) of Group B infants (risk difference, −0.02; 95% confidence interval, −0.14-0.10;
P
=
.68). All fungal isolates remained sensitive to fluconazole, and no drug side effects were documented.
Twice weekly dosing of prophylactic fluconazole can decrease
Candida colonization and invasive infection, cost, and patient exposure in high-risk, preterm infants weighing <1000 grams at birth. We speculate that lower and less frequent dosing may delay or prevent the emergence of antifungal resistance.</description><identifier>ISSN: 0022-3476</identifier><identifier>EISSN: 1097-6833</identifier><identifier>DOI: 10.1016/j.jpeds.2005.03.036</identifier><identifier>PMID: 16126045</identifier><identifier>CODEN: JOPDAB</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Antifungal Agents - administration & dosage ; Antifungal Agents - therapeutic use ; Biological and medical sciences ; Candida albicans - drug effects ; Candida albicans - isolation & purification ; Candidiasis - prevention & control ; Catheterization, Central Venous ; Double-Blind Method ; Drug Administration Schedule ; Female ; Fluconazole - administration & dosage ; Fluconazole - therapeutic use ; General aspects ; Gestational Age ; Humans ; Infant, Newborn ; Infant, Very Low Birth Weight ; Intensive Care Units, Neonatal ; Intubation, Intratracheal ; Male ; Medical sciences ; Microbial Sensitivity Tests ; Risk Factors</subject><ispartof>The Journal of pediatrics, 2005-08, Vol.147 (2), p.172-179</ispartof><rights>2005 Elsevier Inc.</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-fe0508c877e74ad647157bfdd724879b7e3e65a9d01f869d9c51410e0f793663</citedby><cites>FETCH-LOGICAL-c387t-fe0508c877e74ad647157bfdd724879b7e3e65a9d01f869d9c51410e0f793663</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17137620$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16126045$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kaufman, David</creatorcontrib><creatorcontrib>Boyle, Robert</creatorcontrib><creatorcontrib>Hazen, Kevin C.</creatorcontrib><creatorcontrib>Patrie, James T.</creatorcontrib><creatorcontrib>Robinson, Melinda</creatorcontrib><creatorcontrib>Grossman, Leigh B.</creatorcontrib><title>Twice Weekly Fluconazole Prophylaxis for Prevention of Invasive Candida Infection in High-risk Infants of <1000 Grams Birth Weight</title><title>The Journal of pediatrics</title><addtitle>J Pediatr</addtitle><description>We tested the hypothesis that twice weekly prophylactic dosing of fluconazole prevents invasive candidiasis without promoting resistant
Candida species in high-risk, preterm infants.
We compared our previous dosing schedule (Group A) to a less frequent dosing schedule of twice a week (Group B) of fluconazole prophylaxis for up to 6 weeks in a prospective, randomized, double-blind clinical trial in preterm infants weighing <1000 grams at birth and with an endotracheal tube and/or central vascular catheter over a 24-month period. Weekly surveillance cultures were obtained on study patients.
Candida colonization was documented in 5 (12%) of 41 Group A and in 4 (10%) of 40 Group B infants.
Candida sepsis developed in two (5%) of Group A and one (3%) of Group B infants (risk difference, −0.02; 95% confidence interval, −0.14-0.10;
P
=
.68). All fungal isolates remained sensitive to fluconazole, and no drug side effects were documented.
Twice weekly dosing of prophylactic fluconazole can decrease
Candida colonization and invasive infection, cost, and patient exposure in high-risk, preterm infants weighing <1000 grams at birth. We speculate that lower and less frequent dosing may delay or prevent the emergence of antifungal resistance.</description><subject>Antifungal Agents - administration & dosage</subject><subject>Antifungal Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Candida albicans - drug effects</subject><subject>Candida albicans - isolation & purification</subject><subject>Candidiasis - prevention & control</subject><subject>Catheterization, Central Venous</subject><subject>Double-Blind Method</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Fluconazole - administration & dosage</subject><subject>Fluconazole - therapeutic use</subject><subject>General aspects</subject><subject>Gestational Age</subject><subject>Humans</subject><subject>Infant, Newborn</subject><subject>Infant, Very Low Birth Weight</subject><subject>Intensive Care Units, Neonatal</subject><subject>Intubation, Intratracheal</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microbial Sensitivity Tests</subject><subject>Risk Factors</subject><issn>0022-3476</issn><issn>1097-6833</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNp9kM-LEzEUx4Mobl39CwTJRW9TXyYzyQzoQYv7Axb0UPAY0uTFpjtNajKt1qN_uZltYW_Cg5CXz_fl8SHkNYM5Aybeb-abHdo8rwHaOfBS4gmZMehlJTrOn5IZQF1XvJHigrzIeQMAfQPwnFwwwWoBTTsjf5e_vEH6HfF-ONKrYW9i0H_igPRbirv1cdC_faYupnLHA4bRx0Cjo7fhoLM_IF3oYL3VpeHQPLz6QG_8j3WVfL6f2jqMeYp8YGUBep30NtPPPo3r8mvhxpfkmdNDxlfn85Isr74sFzfV3dfr28Wnu8rwTo6VQ2ihM52UKBttRSNZK1fOWlk3nexXEjmKVvcWmOtEb3vTsoYBgpM9F4JfknensbsUf-4xj2rrs8Fh0AHjPivRtXUn2wnkJ9CkmHNCp3bJb3U6KgZqMq826sG8mswr4KWm1Jvz-P1qi_Yxc1ZdgLdnQGejB5d0MD4_cpJxKWoo3McTh8XFwWNS2XgMBq1PxbCy0f93kX_1paJd</recordid><startdate>20050801</startdate><enddate>20050801</enddate><creator>Kaufman, David</creator><creator>Boyle, Robert</creator><creator>Hazen, Kevin C.</creator><creator>Patrie, James T.</creator><creator>Robinson, Melinda</creator><creator>Grossman, Leigh B.</creator><general>Mosby, Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20050801</creationdate><title>Twice Weekly Fluconazole Prophylaxis for Prevention of Invasive Candida Infection in High-risk Infants of <1000 Grams Birth Weight</title><author>Kaufman, David ; Boyle, Robert ; Hazen, Kevin C. ; Patrie, James T. ; Robinson, Melinda ; Grossman, Leigh B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-fe0508c877e74ad647157bfdd724879b7e3e65a9d01f869d9c51410e0f793663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Antifungal Agents - administration & dosage</topic><topic>Antifungal Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Candida albicans - drug effects</topic><topic>Candida albicans - isolation & purification</topic><topic>Candidiasis - prevention & control</topic><topic>Catheterization, Central Venous</topic><topic>Double-Blind Method</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Fluconazole - administration & dosage</topic><topic>Fluconazole - therapeutic use</topic><topic>General aspects</topic><topic>Gestational Age</topic><topic>Humans</topic><topic>Infant, Newborn</topic><topic>Infant, Very Low Birth Weight</topic><topic>Intensive Care Units, Neonatal</topic><topic>Intubation, Intratracheal</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microbial Sensitivity Tests</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kaufman, David</creatorcontrib><creatorcontrib>Boyle, Robert</creatorcontrib><creatorcontrib>Hazen, Kevin C.</creatorcontrib><creatorcontrib>Patrie, James T.</creatorcontrib><creatorcontrib>Robinson, Melinda</creatorcontrib><creatorcontrib>Grossman, Leigh B.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of pediatrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kaufman, David</au><au>Boyle, Robert</au><au>Hazen, Kevin C.</au><au>Patrie, James T.</au><au>Robinson, Melinda</au><au>Grossman, Leigh B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Twice Weekly Fluconazole Prophylaxis for Prevention of Invasive Candida Infection in High-risk Infants of <1000 Grams Birth Weight</atitle><jtitle>The Journal of pediatrics</jtitle><addtitle>J Pediatr</addtitle><date>2005-08-01</date><risdate>2005</risdate><volume>147</volume><issue>2</issue><spage>172</spage><epage>179</epage><pages>172-179</pages><issn>0022-3476</issn><eissn>1097-6833</eissn><coden>JOPDAB</coden><abstract>We tested the hypothesis that twice weekly prophylactic dosing of fluconazole prevents invasive candidiasis without promoting resistant
Candida species in high-risk, preterm infants.
We compared our previous dosing schedule (Group A) to a less frequent dosing schedule of twice a week (Group B) of fluconazole prophylaxis for up to 6 weeks in a prospective, randomized, double-blind clinical trial in preterm infants weighing <1000 grams at birth and with an endotracheal tube and/or central vascular catheter over a 24-month period. Weekly surveillance cultures were obtained on study patients.
Candida colonization was documented in 5 (12%) of 41 Group A and in 4 (10%) of 40 Group B infants.
Candida sepsis developed in two (5%) of Group A and one (3%) of Group B infants (risk difference, −0.02; 95% confidence interval, −0.14-0.10;
P
=
.68). All fungal isolates remained sensitive to fluconazole, and no drug side effects were documented.
Twice weekly dosing of prophylactic fluconazole can decrease
Candida colonization and invasive infection, cost, and patient exposure in high-risk, preterm infants weighing <1000 grams at birth. We speculate that lower and less frequent dosing may delay or prevent the emergence of antifungal resistance.</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>16126045</pmid><doi>10.1016/j.jpeds.2005.03.036</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-3476 |
| ispartof | The Journal of pediatrics, 2005-08, Vol.147 (2), p.172-179 |
| issn | 0022-3476 1097-6833 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68528756 |
| source | ScienceDirect Journals |
| subjects | Antifungal Agents - administration & dosage Antifungal Agents - therapeutic use Biological and medical sciences Candida albicans - drug effects Candida albicans - isolation & purification Candidiasis - prevention & control Catheterization, Central Venous Double-Blind Method Drug Administration Schedule Female Fluconazole - administration & dosage Fluconazole - therapeutic use General aspects Gestational Age Humans Infant, Newborn Infant, Very Low Birth Weight Intensive Care Units, Neonatal Intubation, Intratracheal Male Medical sciences Microbial Sensitivity Tests Risk Factors |
| title | Twice Weekly Fluconazole Prophylaxis for Prevention of Invasive Candida Infection in High-risk Infants of <1000 Grams Birth Weight |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T19%3A45%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Twice%20Weekly%20Fluconazole%20Prophylaxis%20for%20Prevention%20of%20Invasive%20Candida%20Infection%20in%20High-risk%20Infants%20of%20%3C1000%20Grams%20Birth%20Weight&rft.jtitle=The%20Journal%20of%20pediatrics&rft.au=Kaufman,%20David&rft.date=2005-08-01&rft.volume=147&rft.issue=2&rft.spage=172&rft.epage=179&rft.pages=172-179&rft.issn=0022-3476&rft.eissn=1097-6833&rft.coden=JOPDAB&rft_id=info:doi/10.1016/j.jpeds.2005.03.036&rft_dat=%3Cproquest_cross%3E68528756%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c387t-fe0508c877e74ad647157bfdd724879b7e3e65a9d01f869d9c51410e0f793663%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=68528756&rft_id=info:pmid/16126045&rfr_iscdi=true |